Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab

Diagn Pathol. 2014 Jun 7:9:111. doi: 10.1186/1746-1596-9-111.

Abstract

We describe a case of giant cell tumor of the proximal tibia with skip bone metastases of the ipsilateral femur in a 20-year-old man. After the neoadjuvant treatment with denosumab, plain radiographs and computed tomography showed marked osteosclerosis and sclerotic rim formation, and 18F-FDG PET/CT showed a decreased standardized uptake value, whereas magnetic resonance imaging showed diffuse enhancement of the tumor, nearly the same findings as those at pretreatment. Pathological findings of the surgical specimen after the denosumab treatment showed benign fibrous histiocytoma-like features with complete disappearance of both mononuclear stromal cells and multinuclear osteoclast-like giant cells.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1090602085125068.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Bone Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Denosumab
  • Femoral Neoplasms / secondary
  • Fluorodeoxyglucose F18
  • Giant Cell Tumor of Bone / diagnostic imaging
  • Giant Cell Tumor of Bone / drug therapy*
  • Giant Cell Tumor of Bone / secondary
  • Giant Cell Tumor of Bone / surgery
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Multimodal Imaging* / methods
  • Neoadjuvant Therapy*
  • Osteotomy
  • Positron-Emission Tomography
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Tibia / diagnostic imaging
  • Tibia / drug effects*
  • Tibia / pathology
  • Tibia / surgery
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Denosumab